tiprankstipranks
Trending News
More News >

Imugene Limited Announces Cessation of Securities

Story Highlights
Imugene Limited Announces Cessation of Securities

Confident Investing Starts Here:

The latest update is out from Imugene Limited ( (AU:IMU) ).

Imugene Limited announced the cessation of certain securities, including 14,796,793 restricted stock units and 6,666,666 options, due to unmet conditions. This development may impact the company’s capital structure and could influence stakeholder perceptions regarding the company’s operational strategies and future growth prospects.

The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.

More about Imugene Limited

Imugene Limited is a biotechnology company focused on the development of innovative cancer immunotherapies. The company specializes in products that harness the immune system to treat and eradicate tumors, aiming to improve the lives of cancer patients globally.

Average Trading Volume: 24,219,722

Technical Sentiment Signal: Sell

Current Market Cap: A$119.5M

For detailed information about IMU stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App